Market Overview

A Primer On Endpoints: Global Blood Therapeutics

A Primer On Endpoints: Global Blood Therapeutics

The 90 mg GBT440 data presented by Global Blood Therapeutics Inc (NASDAQ: GBT) at the American Society of Hematology meeting showed “consistent and durable responses”.

Wedbush’s Heather Behanna reiterated an Outperform rating on the company, with a price target of $73.

What The Data Revealed

The longer-term data for three months suggest durability of response, the analyst mentioned, while adding, “With no responders in the placebo group, based on these data, we expect the primary endpoint of the pivotal trial to be highly statistically significant.”

Regarding the more direct measures of the mechanism of GBT440, Behanna noted hemoglobin was the primary endpoint for the Phase III study.

Global Blood Therapeutics is also looking at dense red blood cells (RBCs), which is a measure of damaged cells that could correlate with disease morbidity.

Although the numbers are small, the data appear to demonstrate GBT440 is able to stop sickling.

Additional Information

“Our conversations with Global Blood management suggest that there is a correlation between exposure and response of GBT440; however, with variable exposure, this does not closely mirror dose,” Behanna went on to say.

Regarding safety, the company presented safety data when dosed for 28 days or more, with increased dosing durations not revealing any new safety signals. “No one has discontinued due to side effects and GI effects have been mild and transient,” the analyst stated.

The data also revealed there was no on-target toxicities at the studied doses, while most of the drug was cleared within a week after treatment.

At last check, Global Blood shares were down 10 percent at $15.52.

Latest Ratings for GBT

Mar 2020Morgan StanleyMaintainsEqual-Weight
Jan 2020SunTrust Robinson HumphreyDowngradesBuyHold
Jan 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for GBT
View the Latest Analyst Ratings


Related Articles (GBT)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Health Care Reiteration Analyst Ratings Movers Best of Benzinga

Latest Ratings

CALMStephens & Co.Reiterates55.0
PAGStephens & Co.Maintains45.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at